UBS analyst Joshua Spector raised the firm’s price target on Corteva (CTVA) to $90 from $88 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva price target raised to $90 from $87 at BofA
- Corteva price target raised to $85 from $83 at Citi
- Corteva Earnings Call Highlights Growth Amid Headwinds
- Corteva Earns Buy Rating on Strong 1H EBITDA Beat, Higher Guidance and Supportive Crop Chemical Pricing Backdrop
- Notable companies reporting after market close